Third Series of BioGeNe
MarketsandMarkets is here with a platform for pharmaceutical, biotechnology professionals and technology providers to come together at the BioGeNe 2023 Confex on the 8th - 9th February 2023 in San Diego-USA to discuss advancements and solutions to the most critical challenges in the Biomarker, Microbiome and Genome engineering areas.
Biomarker and Companion Diagnostics
Immuno-Oncology
Cancer Biomarkers
Biomarker discovery/ development
Translational research
Clinical Biomarker
Biomarkers in IO and Neurological disorders
Imaging Biomarkers
Pathology
Companion Diagnostics
Next Gen Microbiome and Probiotics
Microbiome discovery
Department of Biochemistry and Immunology
Microbiome science
Microbiology
Biological Science
Gut Biology
Human microbiome
Drug discovery
Therapeutics
Drug discovery businesses have begun to invest in cutting-edge methods for biomarker discovery because of mounting demands related to the success rates of FDA-approved biomarkers and associated diagnostic tests. Speakers are to discuss about Biomarker and Companion Diagnostics and Microbiome and Probiotics. In the past year, the genome editing sector has seen some impressive advancements in the fields of genome writing, base editing, and specific advancements in the treatments using Car-T cells and immunotherapy. Numerous small innovative businesses are present in the market because of the growing emphasis on the development of probiotics products and drugs as well as human microbiome therapies.
The two conferences which are going to be a part of BioGeNe Confex 2023 are, 8th Annual MarketsandMarkets Biomarker and Companion Diagnostics and 5th Annual MarketsandMarkets Next Gen Microbiome and Probiotics .
